Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01929408 · ClinicalTrials.gov registry record
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
A clinical trial, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- 703
- Enrollment target
NCT01929408: Completed study, sponsored by Fred Hutchinson Cancer Center.
NCT01929408 is a clinical trial that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 703 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01929408 has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- 703 participants
- Enrollment target
Study Summary
The purpose of this study is to compare treatment methods and outcomes of patients diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Primary Outcome
Percentage analyzed participants receiving HCT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 703 participants |
| Start Date | 2013-07-19 |
| Est. Completion | 2018-12-04 |
What the finished NCT01929408 record still lists
NCT01929408 is an observational study that tracks outcomes without assigning an intervention. The registered 703 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01929408 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01929408 about?
NCT01929408 is a clinical study titled "Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients". The purpose of this study is to compare treatment methods and outcomes of patients diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
What is the current status of trial NCT01929408?
This trial is currently completed. The enrollment target is 703 participants. The study started on 2013-07-19. Estimated completion is 2018-12-04.
Who is sponsoring clinical trial NCT01929408?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
- NCT06027996 · 702 participants · NA
Melodi Matrix™ in Breast Reconstruction
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI